Slides were washed and nuclei were stained using DAPI (Thermo Fisher Scientific 62248, 1:2,000) for 5 minutes at room temperature, washed, and mounted (Abcam, ab104135)
Liu Qiang, Chairman of YaoPharma, said: "By leveraging Pfizer's exceptional global development experience and commercialisation network, along with YaoPharma's profound expertise in small molecule R&D and manufacturing, our shared goal is to accelerate the global development and commercialisation of this innovative drug, thereby benefiting patients worldwide more rapidly and extensively." Pfizers moves with Metsera and now YaoPharma add to continued competition in the obesity drug market, which has also seen Teva Pharmaceuticals gain US Food and Drug Administration (FDA) approval in August of a generic GLP-1 of its version of Novo Nordisks injectable Saxenda (liraglutide).
Since weight loss is strongly associated with better cardiovascular outcomes, the increasing use of GLP-1 receptor agonists in the treatment of obesity further increases demand
doi: 10.5937/arhfarm73-42160 573 WastykHCPerelmanDTopfMFragiadakisGKRobinsonJLSonnenburgJLet al
